English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates

MPS-Authors
/persons/resource/persons133053

Chari,  A.
Research Group of Structural Biochemistry and Mechanisms, MPI for Biophysical Chemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

3287423.pdf
(Publisher version), 933KB

Supplementary Material (public)
There is no public supplementary material available
Citation

Scheller, N., Mina, L. B., Galão, R. P., Chari, A., Giménez-Barcons, M., Noueiry, A., et al. (2009). Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates. Proceedings of the National Academy of Sciences of the USA, 106(32), 13517-13522. doi:10.1073/pnas.0906413106.


Cite as: https://hdl.handle.net/21.11116/0000-0008-08C8-E
Abstract
Inevitably, viruses depend on host factors for their multiplication. Here, we show that hepatitis C virus (HCV) RNA translation and replication depends on Rck/p54, LSm1, and PatL1, which regulate the fate of cellular mRNAs from translation to degradation in the 5′-3′-deadenylation-dependent mRNA decay pathway. The requirement of these proteins for efficient HCV RNA translation was linked to the 5′ and 3′ untranslated regions (UTRs) of the viral genome. Furthermore, LSm1–7 complexes specifically interacted with essential cis-acting HCV RNA elements located in the UTRs. These results bridge HCV life cycle requirements and highly conserved host proteins of cellular mRNA decay. The previously described role of these proteins in the replication of 2 other positive-strand RNA viruses, the plant brome mosaic virus and the bacteriophage Qß, pinpoint a weak spot that may be exploited to generate broad-spectrum antiviral drugs.